OraSure Technologies, Inc. (NASDAQ:OSUR) Director Charles W. Patrick sold 1,000 shares of OraSure Technologies stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $20.11, for a total value of $20,110.00. Following the completion of the transaction, the director now owns 51,104 shares of the company’s stock, valued at approximately $1,027,701.44. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of OraSure Technologies, Inc. (OSUR) traded up 2.11% during mid-day trading on Friday, hitting $20.84. The company had a trading volume of 698,308 shares. The firm has a market cap of $1.24 billion, a PE ratio of 38.52 and a beta of 1.57. OraSure Technologies, Inc. has a 12-month low of $7.09 and a 12-month high of $21.59. The firm’s 50 day moving average is $19.56 and its 200-day moving average is $15.22.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.02. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The firm had revenue of $40.18 million for the quarter, compared to analyst estimates of $36.54 million. During the same period in the previous year, the company posted $0.07 earnings per share. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. On average, equities analysts expect that OraSure Technologies, Inc. will post $0.48 EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/01/orasure-technologies-inc-osur-director-charles-w-patrick-sells-1000-shares-of-stock.html.

A number of institutional investors have recently modified their holdings of OSUR. SG Americas Securities LLC purchased a new position in shares of OraSure Technologies during the first quarter valued at about $594,000. Parametric Portfolio Associates LLC raised its stake in OraSure Technologies by 103.1% in the first quarter. Parametric Portfolio Associates LLC now owns 178,035 shares of the medical instruments supplier’s stock valued at $2,302,000 after buying an additional 90,361 shares in the last quarter. EAM Investors LLC raised its stake in OraSure Technologies by 20.4% in the first quarter. EAM Investors LLC now owns 411,674 shares of the medical instruments supplier’s stock valued at $5,323,000 after buying an additional 69,678 shares in the last quarter. Prudential Financial Inc. raised its stake in OraSure Technologies by 154.4% in the first quarter. Prudential Financial Inc. now owns 562,867 shares of the medical instruments supplier’s stock valued at $7,278,000 after buying an additional 341,575 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. raised its stake in OraSure Technologies by 20.7% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 20,094 shares of the medical instruments supplier’s stock valued at $260,000 after buying an additional 3,444 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Several research analysts have recently commented on OSUR shares. Stephens reiterated an “overweight” rating and issued a $19.00 target price (up previously from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. BidaskClub lowered OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Saturday, May 6th. Jefferies Group LLC lifted their target price on OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, June 28th. Finally, Canaccord Genuity lifted their target price on OraSure Technologies from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, June 28th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $15.46.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.